Wockhardt slides 2.50% on FDA concerns over Ankleshwar unit

Shares of drug firm Wockhardt today closed 2.53 per cent down on reports that it has received observations from the US health regulator for not adhering to good manufacturing norms at Ankleshwar facility.
As per the United States Food and Drug Administration (USFDA) website the observations in Form 483 notifies the company's management of objectionable conditions.
A mail send to the company remained unanswered at the time of filing the story.
"At the conclusion of an inspection, the FDA Form 483 is presented and discussed with the company's senior management. Companies are encouraged to respond to the FDA Form 483 in writing with their corrective action plan and then implement that corrective action plan expeditiously," as per the information available on the FDA website.

Wockhardt, which has 12 manufacturing plants and three research centres, has been under the regulatory scanner for some time now and had recalled some drugs from the US market during the year.